Mr Samuel Apenteng (left), making a symbolic presentation to Prof Abraham K. Anang, Director, NMIMR Pharmaceutical manufacturer, Intravenous Infusions PLC, has donated 100 cartons of normal saline (IV fluids) to the Noguchi Memorial Institute for Medical Research (NMIMR), University of Ghana.
The fluids, according to Intravenous, would help the Institute and the nine other testing centres across the country to assist in dilution and testing more coronavirus cases and also help to manage patients.
In all, a total of one million litres of fluids were presented to cater for all 10 centres for the rest of the year,against the 176,000 litres which was initially requested by the NMIMR.
Mr Samuel Apenteng, one of the directors of the board of Intravenous Infusions who spoke at the event, said, “for us at Intravenous PLC, we see this presentation as a call to duty to intervene in the current situation that has confronted our country.
As a company, Intravenous is determined to contribute its quota to the fight against the COVID-19 pandemic in Ghana” he noted.
He called on the NMIMR to freely contact the company for more supplies when the need arises to help combat the pandemic.
The Intravenous Infusion, according to Mr Apenteng, is currently on an expansion drive, seeking to produce extra pharmaceutical products to serve the needs of other countries in the West African sub region.
Managing Director Intravenous, Mr. Moukhtar M. Soalihu added that more of such gestures would be offered as part of the company’s solidarity in the fight against the virus.
Director of the NMIMR, Prof Abraham K. Anang who received the items on behalf of the Institute and the nine other testing centres, said, Intravenous Infusions have intervened at the right time.
He noted that the 100 cartons of the fluids which were presented has surpassed the expectations of the Institute as he extended appreciation to the management of the company. Disclaimer
GhanaWeb is not responsible for the reportage or opinions of contributors published on the website. Read our disclaimer.